The Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. We commend the Administration for examining key factors that influence spending on medicines and identifying areas where improvements are needed. We are committed to advancing policies that address misaligned incentives in the biopharmaceutical supply chain and lower out-of-pocket costs for patients.